Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05798923 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
A Phase 2 study of Pulmonary Hypertension, sponsored by OrphAI Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT05798923 is a Phase 2 study of Pulmonary Hypertension that is active but no longer recruiting, run by OrphAI Therapeutics. The registered enrollment target is 10 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05798923, a Phase 2 study of Pulmonary Hypertension, is active but no longer recruiting, sponsored by OrphAI Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
Conditions Studied
Interventions
- DRUG LAM-001
Study Locations (4)
Arizona
- University of Arizona - Tucson
Connecticut
- Yale New Haven Hospital - New Haven
Massachusetts
- Brigham and Women's Hospital - Boston
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05798923
The ClinicalTrials.gov registry entry for NCT05798923 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The listed sponsor is OrphAI Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which LAM-001 is the first listed.
NCT05798923 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05798923 about?
NCT05798923 is a clinical study titled "A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension". This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
What is the current status of trial NCT05798923?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-04-03. Estimated completion is 2027-09-30.
What conditions does trial NCT05798923 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT05798923?
The interventions under investigation include: LAM-001 (DRUG).
Who is sponsoring clinical trial NCT05798923?
This trial is sponsored by OrphAI Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05798923 being conducted?
This trial has 4 study locations across Arizona, Connecticut, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.